Piper Sandler Initiates Coverage On Taysha Gene Therapies with Overweight Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (TSHA) with an Overweight rating and a price target of $9.
April 09, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler initiated coverage on Taysha Gene Therapies with an Overweight rating and a price target of $9.
Analyst ratings, especially from reputable firms like Piper Sandler, can significantly influence investor sentiment and stock prices. An Overweight rating suggests that the analyst believes the stock will outperform its sector or the market. The announcement of a $9 price target, presumably higher than its current trading price, indicates an expectation of upward movement in the stock's price, which could attract more investors to TSHA in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100